Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain

Chemistry and Biology

Volumn 16, Issue 4, 2009, Pages 411-420

  Ahn, Kay ^a   Johnson, Douglas S ^a   Mileni, Mauro ^b   Beidler, David ^a   Long, Jonathan Z ^b   McKinney, Michele K ^b   Weerapana, Eranthie ^b   Sadagopan, Nalini ^c   Liimatta, Marya ^a   Smith, Sarah E ^a   Lazerwith, Scott ^c   Stiff, Cory ^a   Kamtekar, Satwik ^a   Bhattacharya, Keshab ^a   Zhang, Yanhua ^a   Swaney, Stephen ^c   Van Becelaere, Keri ^c   Stevens, Raymond C ^b   Cravatt, Benjamin F ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c PFIZER INC   (United States)

Author keywords

CHEMBIO; MOLNEURO

Indexed keywords

AMIDASE; AMIDE; ANANDAMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; ENZYME INHIBITOR; FATTY ACID AMIDASE; FATTY-ACID AMIDE HYDROLASE; PIPERAZINE; PIPERAZINE DERIVATIVE; PIPERIDINE; PIPERIDINE DERIVATIVE; UREA;

ANIMAL; ARTICLE; BRAIN; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; MALE; METABOLISM; PAIN; RAT; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BRAIN; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; MALE; PAIN; PIPERAZINES; PIPERIDINES; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

MAMMALIA;

EID: 64749114255     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2009.02.013     Document Type: Article

References (52)

1. Ahn K., Johnson D.S., Fitzgerald L.R., Liimatta M., Arendse A., Stevenson T., Lund E.T., Nugent R.A., Nomanbhoy T.K., Alexander J.P., and Cravatt B.F. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 46 (2007) 13019-13030
2. Ahn K., McKinney M.K., and Cravatt B.F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem. Rev. 108 (2008) 1687-1707
3. Alexander J.P., and Cravatt B.F. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem. Biol. 12 (2005) 1179-1187
4. Blankman J.L., Simon G.M., and Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14 (2007) 1347-1356
5. Boger D.L., Sato H., Lerner A.E., Austin B.J., Patterson J.E., Patricelli M.P., and Cravatt B.F. Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition. Bioorg. Med. Chem. Lett. 9 (1999) 265-270
6. Boger D.L., Sato H., Lerner A.E., Hedrick M.P., Fecik R.A., Miyauchi H., Wilkie G.D., Austin B.J., Patricelli M.P., and Cravatt B.F. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc. Natl. Acad. Sci. USA 97 (2000) 5044-5049
7. Bracey M.H., Hanson M.A., Masuda K.R., Stevens R.C., and Cravatt B.F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 298 (2002) 1793-1796
8. Brandl M., Weiss M.S., Jabs A., Suhnel J., and Hilgenfeld R. C-H...pi-interactions in proteins. J. Mol. Biol. 307 (2001) 357-377
9. Chang L., Luo L., Palmer J.A., Sutton S., Wilson S.J., Barbier A.J., Breitenbucher J.G., Chaplan S.R., and Webb M. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br. J. Pharmacol. 148 (2006) 102-113
10. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., and Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996) 83-87
11. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., and Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 98 (2001) 9371-9376
12. Cravatt B.F., Saghatelian A., Hawkins E.G., Clement A.B., Bracey M.H., and Lichtman A.H. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc. Natl. Acad. Sci. USA 101 (2004) 10821-10826
13. Deutsch D.G., Omir R., Arreaza G., Salehani D., Prestwich G.D., Huang Z., and Howlett A. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol. 53 (1997) 255-260
14. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev. Physiol. Biochem. Pharmacol. 160 (2008) 1-24
15. Di Marzo V., Bisogno T., and De Petrocellis L. Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Chem. Biol. 14 (2007) 741-756
16. Dixon W.J. Efficient analysis of experimental observations. Annu. Rev. Pharmacol. Toxicol. 20 (1980) 441-462
17. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 313 (2005) 352-358
18. Fowler C.J. The cannabinoid system and its pharmacological manipulation-a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam. Clin. Pharmacol. 20 (2006) 549-562
19. Glaser S.T., Kaczocha M., and Deutsch D.G. Anandamide transport: a critical review. Life Sci. 77 (2005) 1584-1604
20. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. USA 102 (2005) 18620-18625
21. Hillard C.J., and Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br. J. Pharmacol. 140 (2003) 802-808
22. Holt S., Comelli F., Costa B., and Fowler C.J. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br. J. Pharmacol. 146 (2005) 467-476
23. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., and Vaughan C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 147 (2006) 281-288
24. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9 (2003) 76-81
25. Keith J.M., Apodaca R., Xiao W., Seierstad M., Pattabiraman K., Wu J., Webb M., Karbarz M.J., Brown S., Wilson S., et al. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg. Med. Chem. Lett. 18 (2008) 4838-4843
26. Koutek B., Prestwich G.D., Howlett A.C., Chin S.A., Salehani D., Akhavan N., and Deutsch D.G. Inhibitors of arachidonyl ethanolamide hydrolysis. J. Biol. Chem. 269 (1994) 22937-22940
27. Lambert D.M., Vandevoorde S., Jonsson K.O., and Fowler C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents?. Curr. Med. Chem. 9 (2002) 663-674
28. Leung D., Hardouin C., Boger D.L., and Cravatt B.F. Discovering potent and selective inhibitors of enzymes in complex proteomes. Nat. Biotechnol. 21 (2003) 687-691
29. Leung D., Saghatelian A., Simon G.M., and Cravatt B.F. Inactivation of N-acyl ethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45 (2006) 4720-4726
30. Lichtman A.H., Leung D., Shelton C., Saghatelian A., Hardouin C., Boger D., and Cravatt B.F. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther. 311 (2004) 441-448
31. Lichtman A.H., Shelton C.C., Advani T., and Cravatt B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109 (2004) 319-327
32. Liu Y., Patricelli M.P., and Cravatt B.F. Activity-based protein profiling: the serine hydrolases. Proc. Natl. Acad. Sci. USA 96 (1999) 14694-14699
33. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavon F.J., Serrano A.M., Selley D.E., Parsons L.H., et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 5 (2009) 37-44
34. Massa F., Marsicano G., Hermann H., Cannich A., Monory K., Cravatt B.F., Ferri G.L., Sibaev A., Storr M., and Lutz B. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113 (2004) 1202-1209
35. McFarland M.J., and Barker E.L. Anandamide transport. Pharmacol. Ther. 104 (2004) 117-135
36. McKinney M.K., and Cravatt B.F. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 74 (2005) 411-432
37. Mechoulam R. The Pharmacohistory of Cannabis sativa (1986), CRS Press, Boca Raton, FL
38. Mileni M., Johnson D.S., Wang Z., Everdeen D.S., Liimatta M., Pabst B., Bhattacharya K., Nugent R.A., Kamtekar S., Cravatt B.F., et al. Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc. Natl. Acad. Sci. USA 105 (2008) 12820-12824
39. Moreira F.A., Kaiser N., Monory K., and Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54 (2008) 141-150
40. Naidu P.S., Varvel S.A., Ahn K., Cravatt B.F., Martin B.R., and Lichtman A.H. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl.) 192 (2007) 61-70
41. Nomura D.K., Blankman J.L., Simon G.M., Fujioka K., Issa R.S., Ward A.M., Cravatt B.F., and Casida J.E. Activation of the endocannabinoid system by organophosphorus nerve agents. Nat. Chem. Biol. 4 (2008) 373-378
42. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58 (2006) 389-462
43. Patricelli M.P., Lovato M.A., and Cravatt B.F. Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolase with distinct catalytic features. Biochemistry 38 (1999) 9804-9812
44. Patricelli M.P., Giang D.K., Stamp L.M., and Burbaum J.J. Direct visualization of serine hydrolase activities in complex proteome using fluorescent active site-directed probes. Proteomics 1 (2001) 1067-1071
45. Russo R., Loverme J., La Rana G., Compton T.R., Parrott J., Duranti A., Tontini A., Mor M., Tarzia G., Calignano A., and Piomelli D. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J. Pharmacol. Exp. Ther. 322 (2007) 236-242
46. Saghatelian A., Trauger S.A., Want E.J., Hawkins E.G., Siuzdak G., and Cravatt B.F. Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry 43 (2004) 14332-14339
47. Speers A.E., and Cravatt B.F. Profiling enzyme activities in vivo using click chemistry methods. Chem. Biol. 11 (2004) 535-546
48. Speers A.E., Adam G.C., and Cravatt B.F. Activity-based protein profiling in vivo using a copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J. Am. Chem. Soc. 125 (2003) 4686-4687
49. Swinney D.C. Biochemical mechanisms of drug action: what does it take for success?. Nat. Rev. Drug Discov. 3 (2004) 801-808
50. Tsuboi K., Sun Y.X., Okamoto Y., Araki N., Tonai T., and Ueda N. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J. Biol. Chem. 280 (2005) 11082-11092
51. Wei B.Q., Mikkelsen T.S., McKinney M.K., Lander E.S., and Cravatt B.F. A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem. 281 (2006) 36569-36578
52. Zhang D., Saraf A., Kolasa T., Bhatia P., Zheng G.Z., Patel M., Lannoye G.S., Richardson P., Stewart A., Rogers J.C., et al. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology 52 (2007) 1095-1105